| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GSDMA |
| Uniprot No | Q96QA5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-445aa |
| 氨基酸序列 | MTMFENVTRALARQLNPRGDLTPLDSLIDFKRFHPFCLVLRKRKSTLFWGARYVRTDYTLLDVLEPGSSPSDPTDTGNFGFKNMLDTRVEGDVDVPKTVKVKGTAGLSQNSTLEVQTLSVAPKALETVQERKLAADHPFLKEMQDQGENLYVVMEVVETVQEVTLERAGKAEACFSLPFFAPLGLQGSINHKEAVTIPKGCVLAFRVRQLMVKGKDEWDIPHICNDNMQTFPPGEKSGEEKVILIQASDVGDVHEGFRTLKEEVQRETQQVEKLSRVGQSSLLSSLSKLLGKKKELQDLELALEGALDKGHEVTLEALPKDVLLSKEAVGAILYFVGALTELSEAQQKLLVKSMEKKILPVQLKLVESTMEQNFLLDKEGVFPLQPELLSSLGDEELTLTEALVGLSGLEVQRSGPQYMWDPDTLPRLCALYAGLSLLQQLTKAS |
| 预测分子量 | 49,3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Structural basis of GSDMA activation in pyroptosis"** by Liu et al.
摘要：该研究通过冷冻电镜解析了GSDMA重组蛋白的激活结构，揭示其N端结构域在细胞膜穿孔中的作用，并阐明其与炎性小体信号通路的关联。
2. **"GSDMA promotes tumor apoptosis via mitochondrial permeability transition"** by Wang et al.
摘要：作者发现重组GSDMA蛋白在癌细胞中诱导线粒体膜通透性改变，激活Caspase依赖的凋亡通路，提示其潜在抗肿瘤治疗价值。
3. **"Functional characterization of GSDMA in skin barrier immunity"** by Tanaka et al.
摘要：研究利用重组GSDMA蛋白证明其在表皮细胞焦亡中的关键作用，并发现突变体与特异性皮炎等皮肤免疫疾病的相关性。
4. **"Recombinant GSDMA binds cardiolipin to trigger inflammasome assembly"** by Chen & Zhou
摘要：该文献表明重组GSDMA蛋白通过结合心磷脂促进NLRP3炎性体组装，为感染性疾病中宿主防御机制提供新见解。
**Background of GSDMA Recombinant Protein**
Gasdermin A (GSDMA) is a member of the gasdermin protein family, which plays a critical role in inflammatory cell death (pyroptosis) and immune response regulation. GSDMA is encoded by the *GSDMA* gene, located in a cluster on chromosome 17q21 in humans. It is primarily expressed in epithelial tissues, such as the skin, gastrointestinal tract, and hair follicles, and has been linked to diseases like cancer, psoriasis, and asthma.
Structurally, GSDMA contains a cytotoxic N-terminal domain and a C-terminal inhibitory domain connected by a flexible linker. In resting cells, the C-terminal domain autoinhibits the N-terminal pore-forming activity. Upon cleavage by proteases (e.g., caspase-3. granzymes, or pathogen-derived proteases), the N-terminal fragment oligomerizes and inserts into cell membranes, forming pores that disrupt ion gradients, induce osmotic lysis, and trigger pyroptosis. This process releases pro-inflammatory cytokines and alarmins, amplifying immune responses.
Recombinant GSDMA proteins are engineered in vitro using expression systems (e.g., *E. coli* or mammalian cells) to study its biochemical properties, structural dynamics, and functional mechanisms. These proteins enable researchers to explore GSDMA's role in disease pathways, screen for inhibitors, or develop therapies targeting pyroptosis. For example, recombinant GSDMA variants help elucidate mutations linked to cancer progression or autoimmune disorders.
Current research focuses on harnessing GSDMA's pore-forming ability for cancer immunotherapy or mitigating its hyperactivity in chronic inflammation. The development of recombinant GSDMA tools thus provides a foundation for understanding gasdermin biology and designing precision therapeutics.
×
